Magnus Tobiasson
Overview
Explore the profile of Magnus Tobiasson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gurnari C, Robin M, Ades L, Aljurf M, Almeida A, Duarte F, et al.
Blood
. 2025 Feb;
PMID: 39970324
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment...
2.
Rasmussen B, Nilsson L, Tobiasson M, Jadersten M, Garelius H, Dybedal I, et al.
Genes Chromosomes Cancer
. 2025 Feb;
64(2):e70029.
PMID: 39921387
In myelodysplastic syndromes (MDS), cytogenetic characteristics of the malignant bone marrow cells influence the clinical course. The aim of this study was to evaluate whether cytogenetics is useful to predict...
3.
Rombaut D, Sandmann S, Tekath T, Crouch S, de Graaf A, Smith A, et al.
Hemasphere
. 2025 Jan;
9(1):e70073.
PMID: 39850648
Lower risk (LR) myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem and progenitor disorders caused by the accumulation of somatic mutations in various genes including epigenetic regulators that may produce convergent...
4.
Bernard E, Hasserjian R, Greenberg P, Arango Ossa J, Creignou M, Tuechler H, et al.
Blood
. 2024 Jul;
144(15):1617-1632.
PMID: 38958467
Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by morphologic abnormalities of myeloid cells and peripheral cytopenias. Although genetic abnormalities underlie the pathogenesis of these disorders and their heterogeneity, current...
5.
Sirenko M, Bernard E, Creignou M, Domenico D, Farina A, Arango Ossa J, et al.
Blood
. 2024 Apr;
144(11):1221-1229.
PMID: 38687605
Mutations in UBA1, which are disease-defining for VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, have been reported in patients diagnosed with myelodysplastic syndromes (MDS). Here, we define the prevalence...
6.
Creignou M, Bernard E, Gasparini A, Tranberg A, Todisco G, Moura P, et al.
J Intern Med
. 2024 Apr;
296(1):53-67.
PMID: 38654517
Background: The Molecular International Prognostic Scoring System (IPSS-M) is the new gold standard for diagnostic outcome prediction in patients with myelodysplastic syndromes (MDS). This study was designed to assess the...
7.
Bernard E, Tuechler H, Greenberg P, Hasserjian R, Arango Ossa J, Nannya Y, et al.
NEJM Evid
. 2024 Feb;
1(7):EVIDoa2200008.
PMID: 38319256
BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are...
8.
Campillo-Marcos I, Casado-Pelaez M, Davalos V, Ferrer G, Mata C, Mereu E, et al.
Cancer Res Commun
. 2024 Feb;
4(2):365-377.
PMID: 38300528
Significance: MDS are myeloid clonal hemopathies with a low 5-year survival rate, and approximately half of the cases do not respond to standard HMA therapy. Our innovative single-cell multiomics approach...
9.
Tobiasson M, Pandzic T, Illman J, Nilsson L, Westrom S, Ejerblad E, et al.
J Clin Oncol
. 2024 Jan;
42(12):1378-1390.
PMID: 38232336
Purpose: Clinical relapse is the major threat for patients with myelodysplastic syndrome (MDS) undergoing hematopoietic stem-cell transplantation (HSCT). Early detection of measurable residual disease (MRD) would enable preemptive treatment and...
10.
Dimitriou M, Mortera-Blanco T, Tobiasson M, Mazzi S, Lehander M, Hogstrand K, et al.
Blood
. 2023 Dec;
143(11):953-966.
PMID: 38096358
Relapse after complete remission (CR) remains the main cause of mortality after allogeneic stem cell transplantation for hematological malignancies and, therefore, improved biomarkers for early prediction of relapse remains a...